173 related articles for article (PubMed ID: 23083502)
21. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
22. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
24. Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment.
Richards D; Ayala AA; Wu Y; Middleton LP
Oncol Ther; 2020 Jun; 8(1):81-89. PubMed ID: 32700071
[TBL] [Abstract][Full Text] [Related]
25. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
26. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
Vogl G; Dietze O; Hauser-Kronberger C
Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
[TBL] [Abstract][Full Text] [Related]
27. Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up.
Ringberg A; Andersson I; Aspegren K; Linell F
Eur J Surg Oncol; 1991 Oct; 17(5):466-76. PubMed ID: 1657650
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
29. Screening mammography-detected ductal carcinoma in situ: mammographic features based on breast cancer subtypes.
Kim MY; Kim HS; Choi N; Yang JH; Yoo YB; Park KS
Clin Imaging; 2015; 39(6):983-6. PubMed ID: 26259866
[TBL] [Abstract][Full Text] [Related]
30. A clinico-pathological study on cancer in sclerosing adenosis.
Ogura K; Horii R; Oosako T; Iwase T; Akiyama F
Breast Cancer; 2014 Nov; 21(6):732-7. PubMed ID: 23408123
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive carcinoma of the breast presenting in adenosis.
Oberman HA; Markey BA
Mod Pathol; 1991 Jan; 4(1):31-5. PubMed ID: 1850517
[TBL] [Abstract][Full Text] [Related]
32. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
[TBL] [Abstract][Full Text] [Related]
34. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Facina G; Lopes-Costa PV; Dos Santos AR; De Vasconcelos-Valença RJ; Pinho-Sobral AL; Ferreira-Filho CP; Alencar AP; Gebrim LH; Da Silva BB
Diagn Cytopathol; 2010 Apr; 38(4):235-8. PubMed ID: 19790246
[TBL] [Abstract][Full Text] [Related]
36. Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study.
Keymeulen KBIM; Geurts SME; Kooreman LFS; Duijm LEM; Engelen S; Vanwetswinkel S; Luiten E; Siesling S; Voogd AC; Tjan-Heijnen VCG
Eur Radiol; 2023 Mar; 33(3):2209-2217. PubMed ID: 36180645
[TBL] [Abstract][Full Text] [Related]
37. Sonographic findings of pure ductal carcinoma in situ.
Lee MH; Ko EY; Han BK; Shin JH; Ko ES; Hahn SY
J Clin Ultrasound; 2013 Oct; 41(8):465-71. PubMed ID: 23949917
[TBL] [Abstract][Full Text] [Related]
38. Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma.
Liu W; Li W; Li Z; Shi L; Zhao P; Guo Z; Tian J; Wang Z
Breast Cancer Res Treat; 2020 May; 181(1):127-134. PubMed ID: 32227257
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype.
VandenBussche CJ; Elwood H; Cimino-Mathews A; Bittar Z; Illei PB; Warzecha HN
Hum Pathol; 2013 Nov; 44(11):2487-93. PubMed ID: 24029706
[TBL] [Abstract][Full Text] [Related]
40. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
